The job of the board and leadership is to maximise value for shareholders. The dog stuff has a very low value compared to human use plus it presents a risk that the human value proposition would likely be severely impacted. I see the dog stuff as a means to an ends and would be an unnecessary & detrimental distraction at this pivotal stage.
I think the board has it right, you think the board has it wrong, life goes on.
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-436
-
- There are more pages in this discussion • 543 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $31.34K | 179.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 221263 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 345122 | 6 |
View Market Depth
| Last trade - 12.47pm 11/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |